Mizuho analyst Graig Suvannavejh raised the firm’s price target on Ideaya Biosciences (IDYA) to $46 from $44 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q3 report.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position
- IDEAYA Biosciences Reports Strong Q3 2025 Results
- IDEAYA Biosciences: Promising Clinical Developments and Strategic Potential Drive Buy Rating
- IDEAYA Biosciences: Strong Clinical Data and Financial Position Justify Buy Rating
- Ideaya Biosciences price target raised to $79 from $74 at JPMorgan